Tislelizumab
Pulmonary Metastasis
Fudan Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Pulmonary Metastasis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Theprubicin Zhejiang Cancer Hospital | Phase 2/3 | B |
Rivoceranib Zhejiang Cancer Hospital | Phase 2/3 | B |
Ethiodized Oil Zhejiang Cancer Hospital | Phase 2/3 | B |
Same molecule, other indications
Tislelizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →